São Tomé Health Minister Acknowledges System Deterioration While Noting Improvements
Read more
Noticias ao Minuto
noticiasaominuto.com

São Tomé Health Minister Acknowledges System Deterioration While Noting Improvements

The Health Minister of São Tomé acknowledged the negative results of the Ibragim African Management Index (IIAG), which classified the country as the second in Africa with the greatest deterioration in the health sector over the last decade; however, he also highlighted recent positive changes.

In an interview with Lusa in São Tomé, Celso Matos stated: 'It is true. Over the last 10 years, we have regressed in some health parameters. In others, we have improved, but in others, we have regressed.'

Nevertheless, the minister clarified that this result pertains to the period from 2016 to 2025, whereas the current executive branch has only been in office for the last two years. Celso Matos noted: 'It is important to make clear that this is not the Government's fault. Moreover, I have an image here that shows that the greatest deterioration occurred in 2024. (...) Stabilization was observed in 2025.'

Among the achievements, the orthopedic doctor, who previously held the position of head of the Medical Order of São Tomé and Príncipe, pointed out improvements in malaria control indicators. In 2024, over seven thousand cases were recorded, almost double the previous year, but in 2025, there was a 'decrease' to four or five thousand cases.

Celso Matos also indicated progress in infectious disease control, particularly HIV, calling the results 'very good,' as well as in access to healthcare. He emphasized: 'We have medical posts almost throughout the country. We have increased the number of doctors for districts, and we have an orientation towards primary healthcare, whose mission is to have one doctor for every medical post in this country, and we are not far from achieving this goal.'

He added that this is being done specifically to improve people's access to medical care, and that primary level services need to be equipped with a large number of medicines and diagnostic tools.

Regarding the indicators that have deteriorated or require further improvement, Celso Matos noted that many of them do not depend solely or predominantly on the health sector. Concerning the control of non-communicable diseases, Matos admitted that 'this is a serious problem in the health system of São Tomé and Príncipe,' pointing to the sharp rise in cardiovascular incidents (strokes), diabetes, and arterial hypertension, as well as other diseases caused by nutrition, hygiene, and lack of physical activity.

The minister stated: 'We realize that non-communicable diseases are the most costly for the system. Besides the impact on human health, they are the most expensive. And our country does not have the money for (...) providing the quality of care that people need.'

He reported the creation of a department for chronic non-communicable diseases. This department has a team, a strategic program developed for non-communicable diseases and a strategic program for oncological diseases, and staff training has been conducted for oncological accounting and management at the primary level, and primary level administrators have been trained to improve the situation.'

However, the minister stressed that the implementation of all these strategic plans requires funding, which is a major problem. He noted that the health system of São Tomé and Príncipe, despite significant expenditures, is a system that is 'free, in quotes,' reflecting the real cost borne by the state.

According to Celso Matos, the lack of funding hinders several measures, such as modernizing hospital equipment, retaining human resources, and timely procurement of medicines and consumables.

Nevertheless, he assured that he would leave documents and guidelines for the next health minister, who is expected to take office in the coming weeks after the formation of a new Government following the September 27 elections.

Similar stories

Prime Minister Modi called Sharad Pawar, who is hospitalized at Breach Candy Hospital
Read more
www.aajtak.in

Prime Minister Modi called Sharad Pawar, who is hospitalized at Breach Candy Hospital

Following the deterioration of the health of NCP (SP) chief Sharad Pawar, he was admitted to Breach Candy Hospital in Mumbai for examination. At this time, Prime Minister Narendra Modi contacted Sharad Pawar by phone to inquire about his well-being. This call sparked new political discussions in Maharashtra.

Vittal Maniyar, a close friend and relative of Sharad Pawar, confirmed the phone conversation with Prime Minister Modi. He stated that on Wednesday morning, Prime Minister Modi called Sharad Pawar to ask about his health and advised him to focus on his recovery and rest completely.

During the conversation, Prime Minister Modi told Sharad Pawar: 'Supriya and I will take care of the country. Please take care of your health and rest. May your blessings remain with us.'

In response to Prime Minister Modi's words, Sharad Pawar expressed gratitude for the call. He told the Prime Minister: 'When you are all together, I do not worry about the country.'

Earlier, Sharad Pawar had been hospitalized at Ruby Hall Clinic in Pune due to complaints of chest tightness and cough. After two days of treatment and regular check-ups, he was discharged from the hospital on Wednesday. He then returned to his home 'Silver Oak' in Mumbai with his daughter and Lok Sabha MP Supriya Sule.

Supriya Sule wrote on social media 'X', stating: 'Baba is much better now, and we are going to Mumbai. Thank you very much to the entire Ruby Hall team for such care. Heartfelt thanks to everyone for the good wishes.'

However, Supriya Sule later clarified that Sharad Pawar was hospitalized at Breach Candy Hospital for the next stage of medical examination.

FDA approves generic version of lenacapavir, monthly injection against HIV
Read more
super.abril.com.br

FDA approves generic version of lenacapavir, monthly injection against HIV

The Food and Drug Administration (FDA), the US regulatory body, granted provisional approval to the first generic version of lenacapavir. This medication is an injection administered semi-annually and offers near-complete protection against HIV infection.

The generic, produced by the Indian pharmaceutical company Dr. Reddy’s Laboratories, cannot be marketed in the US due to patent protection of the original drug. However, it can be acquired by the American government for PEPFAR, a program aimed at combating HIV abroad.

Both Dr. Reddy’s and Unitaid, a global health initiative that supported the development of the generic, aim to ensure this medication reaches low- and middle-income nations.

Dr. Reddy’s is one of six pharmaceutical companies authorized by Gilead Sciences, the creator of lenacapavir, to produce the lower-cost version. In 2024, licenses were issued to companies located in Asia and North Africa. Currently, only Dr. Reddy’s has FDA approval, but all six can distribute the medicine in 120 countries after obtaining the necessary permits. This list includes areas with high HIV rates, such as South Africa, Lesotho, Botswana, and Zimbabwe.

The annual cost of Dr. Reddy’s generic will be 40 dollars per patient. This price was established in 2025 through an agreement signed with three health entities: Unitaid, the Clinton Health Access Initiative (CHAI), and the South African institute Wits RHI. The first doses are expected to reach the countries by the end of 2026, with supply expansion anticipated in 2027.

Lenacapavir, which is injectable and applied twice a year, may represent a more effective alternative for HIV pre-exposure prophylaxis (PrEP) compared to daily pills, whose effectiveness depends on constant adherence.

The substance had already been marketed by Gilead since 2022 for HIV treatment. In 2025, it was approved in the US for prevention purposes, following clinical trials that demonstrated nearly 100% protection. In one of these studies, none of the treated women contracted the infection, and in another, only two of the 2,179 participants who used lenacapavir contracted the virus.

In 2024, Science magazine named lenacapavir the 'Advance of the Year,' recognizing the fundamental research that underpinned the drug. However, the high cost in the US, reaching about 28 thousand dollars annually, posed a major obstacle to its widespread availability.

According to Unitaid, even before the arrival of the generic, more than 125,000 individuals in ten African countries were already using Gilead-manufactured lenacapavir on an early basis. The organization emphasizes that the generic obtained 'provisional approval' from the FDA, which is the standard status for generics while the original product remains under protection.

Manipal signs 30-year lease agreement with Thakral to build 500-bed hospital in Gurugram
Read more
business-standard.com

Manipal signs 30-year lease agreement with Thakral to build 500-bed hospital in Gurugram

Manipal Health Enterprises has signed a long-term lease agreement with the investment firm Thakral Corporation, whose shares are listed on the Singapore Exchange Mainboard, to create and manage a multi-specialty hospital in Gurugram.

Under the terms of the deal between Manipal and Thakral's Indian subsidiary, TIL Investments, the company will be responsible for the construction, operation, management, and maintenance of the medical facility on a plot of approximately 3.5 acres over 30 years.

According to regulatory filings by the Temasek-backed hospital network, the first phase of the planned hospital is expected to accommodate up to 500 beds.

Although the company did not disclose the exact investment amount, the filings indicated that the land has good connectivity to Indira Gandhi International Airport and other major infrastructure hubs, and is located near future residential complexes and infrastructure projects.

Dilip Jose, CEO of Manipal Health Enterprises, previously told Business Standard that building a new 250-bed hospital typically requires an investment of 380–390 crore rupees, excluding land and building costs.

He added that the cost for medical equipment, technology, information systems, and interior finishing amounts to approximately 1.5 crore rupees per bed. Based on this figure, the estimated cost of the project in Gurugram could be around 750 crore rupees.

Based on this flagship hospital, Manipal's board of directors proposed developing an integrated healthcare and wellness ecosystem that would complement the hospital's specialized care and be supported by hospitality and retail offerings.

Jose noted that the Delhi NCR is a vital market for Manipal Hospitals, and the new hospital in Gurugram will help strengthen the company's presence in the region and meet growing healthcare demands.

Jose had previously stated that Manipal is open to acquisitions in addition to organic growth, assessing opportunities in Kerala, Hyderabad, Delhi NCR, and Visakhapatnam.

Currently, the firm manages 12,600 beds across 49 hospitals nationwide, in addition to operating three facilities in the Delhi-NCR region.

The announcement was made after the close of trading. On Wednesday, Manipal Health Enterprises shares rose by 3.58 percent, closing at 667.70 rupees per share on the BSE.

Popular